ArticleMolecular oncology2019

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.

Zay Yar Oo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.